
Could blockbuster diabetes and weight-loss meds such as Ozempic, Wegovy, Mounjaro and Zepbound also lower users’ odds for colon cancer? New research suggests they might. All of these medications (and more) fall into a class of diabetes drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The new study, from researchers at Case Western Reserve… read on > read on >